LinkedIn Image Decision Points: Key Decisions for Nurses in the Care of Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma

Decision Points: Key Decisions for Nurses in the Care of Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma

View Activity

Activity Features

CME-Certified

Expert Discussion

Interactive Presentation

Opinion Poll

prIME Points™

View Activity

Provider

This activity is provided by prIME Oncology.

Activity Date

RELEASE DATE
August 30, 2017

EXPIRATION DATE
August 30, 2018

Activity Overview

Hear from expert clinical nurses on the appropriate management of patients being treated for chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL), including discussion of monitoring adverse events, signs of progression, and overall patient quality of life. This interactive case presentation will provide you with information on evidence-based treatment strategies and enable you to apply this information in patient scenarios.

Faculty

  • Ebony Mayo, BSN, MBAEmory University
    Atlanta, Georgia
  • Kaitlin Kennard, BSN, RNAbramson Cancer Center of the University of Pennsylvania
    Philadelphia, Pennsylvania

Topics

  • Care of patients receiving targeted agents for the treatment of CLL or iNHL
  • Adverse event management for patients with CLL or iNHL

Target Audience

This educational activity is designed to meet the needs of oncology nurses involved in the treatment of patients with CLL and iNHL.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Select optimal treatment options for patients with CLL and iNHL based on the accurate assessment of patient and disease characteristics
  • Identify the unique features associated with the use of oral targeted therapies that have the potential to impact quality of life and adherence to therapy
  • Assess the most recent clinical data focused on novel therapeutic interventions
  • Evaluate strategies to mitigate treatment-related adverse events

Continuing Education

This continuing nursing education activity was approved by the ONS, an accredited approver by the American Nurses Credentialing Center’s COA.

A maximum of 0.75 contact hours may be earned for successful completion of this program. The criteria for successful completion include attending the full program and completing the evaluation.

Content in this learning activity is applicable to meeting individual requirements for certification renewal through the Oncology Nursing Certification Corporation’s Independent Learning Needs Assessment (ILNA) renewal method.  Visit www.oncc.org for complete details on oncology nursing certification.

CME and Disclosure Information

Support

This educational activity is supported by a grant from Gilead Sciences, Inc.